Selective κ Opioid Antagonists nor-BNI, GNTI and JDTic Have Low Affinities for Non-Opioid Receptors and Transporters
暂无分享,去创建一个
Bryan L. Roth | Nicola A. Colabufo | F. Ivy Carroll | Cécile Béguin | Bruce M. Cohen | B. Cohen | Xi-Ping Huang | B. Roth | N. Colabufo | W. Carlezon | F. Carroll | M. Perrone | A. Van’t Veer | Thomas A. Munro | William A. Carlezon | Maria Grazia Perrone | Xi-Ping Huang | Carmela Inglese | Ashlee Van't Veer | C. Inglese | C. Béguin | Ashlee Van’t Veer | Cécile Béguin
[1] Andrew Coop,et al. Kappa opioid antagonists: Past successes and future prospects , 2005, The AAPS Journal.
[2] Graeme Milligan,et al. Allostery at G Protein-Coupled Receptor Homo- and Heteromers: Uncharted Pharmacological Landscapes , 2010, Pharmacological Reviews.
[3] Y. Daali,et al. P‐glycoprotein is not involved in the differential oral potency of naloxone and naltrexone , 2009, Fundamental & clinical pharmacology.
[4] Allison T. Knoll,et al. Dynorphin, stress, and depression , 2010, Brain Research.
[5] Cécile Béguin,et al. Kappa-opioid ligands in the study and treatment of mood disorders. , 2009, Pharmacology & therapeutics.
[6] F. Monsma,et al. Moving from the Orphanin FQ Receptor to an Opioid Receptor Using Four Point Mutations* , 1996, The Journal of Biological Chemistry.
[7] P. Voorn,et al. Dynorphin displaces binding at the glycine site of the NMDA receptor in the rat striatum , 2007, Neuroscience Letters.
[8] B. Cohen,et al. Medicinal Chemistry of Kappa Opioid Receptor Antagonists , 2009 .
[9] Maria F. Sassano,et al. Automated design of ligands to polypharmacological profiles , 2012, Nature.
[10] S. Inan. Pharmacological and neuroanatomical analysis of GNTI-induced repetitive behavior in mice , 2010 .
[11] N. Dun,et al. Inhibitory effect of lidocaine on pain and itch using formalin-induced nociception and 5'-guanidinonaltrindole-induced scratching models in mice: behavioral and neuroanatomical evidence. , 2009, European journal of pharmacology.
[12] Bryan L. Roth,et al. Structure of the Nociceptin/Orphanin FQ Receptor in Complex with a Peptide Mimetic , 2012, Nature.
[13] Francesco Berardi,et al. Perspectives of P-glycoprotein modulating agents in oncology and neurodegenerative diseases: pharmaceutical, biological, and diagnostic potentials. , 2010, Journal of medicinal chemistry.
[14] S. Husbands,et al. In vivo and in vitro characterization of naltrindole-derived ligands at the κ-opioid receptor , 2013, Journal of psychopharmacology.
[15] P. Plenge,et al. An affinity-modulating site on neuronal monoamine transport proteins. , 1997, Pharmacology & toxicology.
[16] Y. Kuraishi,et al. Noradrenergic regulation of itch transmission in the spinal cord mediated by α-adrenoceptors , 2011, Neuropharmacology.
[17] M. Bruchas,et al. Long-Acting κ Opioid Antagonists Disrupt Receptor Signaling And Produce Noncompetitive Effects By Activating C-Jun N-Terminal Kinase* , 2007, Journal of Biological Chemistry.
[18] B. Cohen,et al. Duration of Action of a Broad Range of Selective κ-Opioid Receptor Antagonists Is Positively Correlated with c-Jun N-Terminal Kinase-1 Activation , 2011, Molecular Pharmacology.
[19] A. Cowan,et al. Kappa-Opioid Antagonists as Pruritogenic Agents , 2009 .
[20] Stephen A. Wring,et al. Passive Permeability and P-Glycoprotein-Mediated Efflux Differentiate Central Nervous System (CNS) and Non-CNS Marketed Drugs , 2002, Journal of Pharmacology and Experimental Therapeutics.
[21] N. Dun,et al. Investigation of gastrin-releasing peptide as a mediator for 5′-guanidinonaltrindole-induced compulsive scratching in mice , 2011, Peptides.
[22] R. Raffa,et al. Pilocarpine-induced reciprocal hindlimb scratching in mice , 1987, Pharmacology Biochemistry and Behavior.
[23] M. Heilig,et al. The kappa opioid receptor antagonist JDTic attenuates alcohol seeking and withdrawal anxiety , 2012, Addiction biology.
[24] F. L. Moore,et al. A subset of kappa opioid ligands bind to the membrane glucocorticoid receptor in an amphibian brain. , 2000, Endocrinology.
[25] N. Dun,et al. Nalfurafine prevents 5′-guanidinonaltrindole- and compound 48/80-induced spinal c-fos expression and attenuates 5′-guanidinonaltrindole-elicited scratching behavior in mice , 2009, Neuroscience.
[26] M. Nitta,et al. Structure-activity relationship study on alpha1 adrenergic receptor antagonists from beer. , 2009, Bioorganic & medicinal chemistry letters.
[27] J. Kamei,et al. Norbinaltorphimine, a selective kappa-opioid receptor antagonist, induces an itch-associated response in mice. , 2001, European journal of pharmacology.
[28] R. Bodnar,et al. Reductions in locomotor activity following central opioid receptor subtype antagonists in rats , 1996, Physiology & Behavior.
[29] R. Lewis,et al. Conopeptide ρ-TIA Defines a New Allosteric Site on the Extracellular Surface of the α1B-Adrenoceptor*♦ , 2012, The Journal of Biological Chemistry.
[30] S. Yamada,et al. Characterization of specific [3H]nociceptin binding in rat brain and spinal cord. , 2001, Biological & pharmaceutical bulletin.
[31] A. Levine,et al. Nor-binaltorphimine decreases deprivation and opioid-induced feeding , 1990, Brain Research.
[32] J. Docherty. Subtypes of functional α1-adrenoceptor , 2010, Cellular and Molecular Life Sciences.
[33] R. Raffa,et al. Evidence that reciprocal hindlimb scratching elicited in mice by intrathecal administration of muscarinic agonists is mediated through M1 type receptors. , 1987, Life sciences.
[34] T. Endoh,et al. Nor-binaltorphimine: a potent and selective kappa-opioid receptor antagonist with long-lasting activity in vivo. , 1992, Archives internationales de pharmacodynamie et de therapie.
[35] Bryan L. Roth,et al. Structure of the human kappa opioid receptor in complex with JDTic , 2012, Nature.
[36] Kristina Luthman,et al. Caco-2 monolayers in experimental and theoretical predictions of drug transport1PII of original article: S0169-409X(96)00415-2. The article was originally published in Advanced Drug Delivery Reviews 22 (1996) 67–84.1 , 2001 .
[37] I. Hidalgo,et al. Assessing the absorption of new pharmaceuticals. , 2001, Current topics in medicinal chemistry.
[38] B. Cohen,et al. Long-acting κ opioid antagonists nor-BNI, GNTI and JDTic: pharmacokinetics in mice and lipophilicity , 2012, BMC pharmacology.
[39] P. Wellman. Norepinephrine and the control of food intake. , 2000, Nutrition.
[40] D. Perez. Structure–function of α1-adrenergic receptors , 2007 .
[41] M. Braude,et al. Preclinical toxicity studies of naltrexone. , 1976, NIDA research monograph.
[42] D. Lambert,et al. Pharmacological characterization of the nociceptin / orphanin FQ receptor antagonist SB-612111: in vivo studies , 2007 .
[43] Hong Zou,et al. Effect of GNTI, a kappa opioid receptor antagonist, on MK-801-induced hyperlocomotion and stereotypy in mice , 2006, Acta Pharmacologica Sinica.
[44] A. Levine,et al. The kappa-opioid antagonist GNTI reduces U50,488-, DAMGO-, and deprivation-induced feeding, but not butorphanol- and neuropeptide Y-induced feeding in rats , 2001, Brain Research.
[45] Willem Soudijn,et al. Allosteric modulation of G-protein-coupled receptors , 2001 .
[46] Quantification of Functional Selectivity at the Human α1A-Adrenoceptor , 2011, Molecular Pharmacology.
[47] A. Ford,et al. Facilitatory Interplay in α1a and β2 Adrenoceptor Function Reveals a Non-Gq Signaling Mode: Implications for Diversification of Intracellular Signal Transduction , 2009, Molecular Pharmacology.
[48] D. Lambert,et al. Pharmacological Characterization of the Nociceptin/Orphanin FQ Receptor Antagonist SB-612111 [(–)-cis-1-Methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol]: In Vitro Studies , 2007, Journal of Pharmacology and Experimental Therapeutics.
[49] B. Cohen,et al. Repeated Exposure to the κ-Opioid Receptor Agonist Salvinorin A Modulates Extracellular Signal-Regulated Kinase and Reward Sensitivity , 2011, Biological Psychiatry.
[50] H. Yamamura,et al. Extremely long-lasting antagonistic actions of nor-binaltorphimine (nor-BNI) in the mouse tail-flick test. , 1992, The Journal of pharmacology and experimental therapeutics.
[51] W. Klemm,et al. Alpha noradrenergic agonists promote catalepsy in the mouse , 1988, Pharmacology Biochemistry and Behavior.
[52] E. Nielsen,et al. Validation of a fluorescence-based high-throughput assay for the measurement of neurotransmitter transporter uptake activity , 2008, Journal of Neuroscience Methods.
[53] R. Westerink,et al. Caveats and limitations of plate reader-based high-throughput kinetic measurements of intracellular calcium levels. , 2011, Toxicology and applied pharmacology.
[54] K. Luthman,et al. Caco-2 monolayers in experimental and theoretical predictions of drug transport. , 2001, Advanced drug delivery reviews.
[55] S. Lazareno,et al. Allosteric interactions between the antagonist prazosin and amiloride analogs at the human alpha(1A)-adrenergic receptor. , 2000, Molecular pharmacology.
[56] N. Mello,et al. Kappa opioid antagonist effects of the novel kappa antagonist 5′-guanidinonaltrindole (GNTI) in an assay of schedule-controlled behavior in rhesus monkeys , 2002, Psychopharmacology.
[57] F. Ehlert,et al. Selectivity of Agonists for the Active State of M1 to M4 Muscarinic Receptor Subtypes , 2009, Journal of Pharmacology and Experimental Therapeutics.
[58] S. Knapp,et al. Structural Determinants of G-protein α Subunit Selectivity by Regulator of G-protein Signaling 2 (RGS2)* , 2009, The Journal of Biological Chemistry.
[59] D. Perez,et al. Binding, partial agonism, and potentiation of alpha(1)-adrenergic receptor function by benzodiazepines: A potential site of allosteric modulation. , 1999, The Journal of pharmacology and experimental therapeutics.
[60] R. Stevens,et al. Structure of the human k-opioid receptor in complex with JDTic , 2012 .